APYX Relative Valuation
APYX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, APYX is overvalued; if below, it's undervalued.
Historical Valuation
Apyx Medical Corp (APYX) is now in the Fair zone, suggesting that its current forward PS ratio of 2.68 is considered Fairly compared with the five-year average of -10.15. The fair price of Apyx Medical Corp (APYX) is between 2.64 to 8.31 according to relative valuation methord.
Relative Value
Fair Zone
2.64-8.31
Current Price：3.46
Fair
-9.31
PE
1Y
3Y
5Y
-19.38
EV/EBITDA
Apyx Medical Corp. (APYX) has a current EV/EBITDA of -19.38. The 5-year average EV/EBITDA is -15.40. The thresholds are as follows: Strongly Undervalued below -36.81, Undervalued between -36.81 and -26.10, Fairly Valued between -4.69 and -26.10, Overvalued between -4.69 and 6.01, and Strongly Overvalued above 6.01. The current Forward EV/EBITDA of -19.38 falls within the Historic Trend Line -Fairly Valued range.
-14.03
EV/EBIT
Apyx Medical Corp. (APYX) has a current EV/EBIT of -14.03. The 5-year average EV/EBIT is -9.87. The thresholds are as follows: Strongly Undervalued below -23.21, Undervalued between -23.21 and -16.54, Fairly Valued between -3.20 and -16.54, Overvalued between -3.20 and 3.47, and Strongly Overvalued above 3.47. The current Forward EV/EBIT of -14.03 falls within the Historic Trend Line -Fairly Valued range.
2.68
PS
Apyx Medical Corp. (APYX) has a current PS of 2.68. The 5-year average PS is 3.39. The thresholds are as follows: Strongly Undervalued below -2.09, Undervalued between -2.09 and 0.65, Fairly Valued between 6.14 and 0.65, Overvalued between 6.14 and 8.88, and Strongly Overvalued above 8.88. The current Forward PS of 2.68 falls within the Historic Trend Line -Fairly Valued range.
-8.68
P/OCF
Apyx Medical Corp. (APYX) has a current P/OCF of -8.68. The 5-year average P/OCF is -6.86. The thresholds are as follows: Strongly Undervalued below -37.70, Undervalued between -37.70 and -22.28, Fairly Valued between 8.57 and -22.28, Overvalued between 8.57 and 23.99, and Strongly Overvalued above 23.99. The current Forward P/OCF of -8.68 falls within the Historic Trend Line -Fairly Valued range.
-8.28
P/FCF
Apyx Medical Corp. (APYX) has a current P/FCF of -8.28. The 5-year average P/FCF is -10.72. The thresholds are as follows: Strongly Undervalued below -30.81, Undervalued between -30.81 and -20.77, Fairly Valued between -0.68 and -20.77, Overvalued between -0.68 and 9.36, and Strongly Overvalued above 9.36. The current Forward P/FCF of -8.28 falls within the Historic Trend Line -Fairly Valued range.
Apyx Medical Corp (APYX) has a current Price-to-Book (P/B) ratio of 22.63. Compared to its 3-year average P/B ratio of 5.83 , the current P/B ratio is approximately 288.45% higher. Relative to its 5-year average P/B ratio of 5.69, the current P/B ratio is about 297.57% higher. Apyx Medical Corp (APYX) has a Forward Free Cash Flow (FCF) yield of approximately -6.61%. Compared to its 3-year average FCF yield of -17.97%, the current FCF yield is approximately -63.22% lower. Relative to its 5-year average FCF yield of -13.38% , the current FCF yield is about -50.61% lower.
22.63
P/B
Median3y
5.83
Median5y
5.69
-6.61
FCF Yield
Median3y
-17.97
Median5y
-13.38
Competitors Valuation Multiple
The average P/S ratio for APYX's competitors is 6.61, providing a benchmark for relative valuation. Apyx Medical Corp Corp (APYX) exhibits a P/S ratio of 2.68, which is -59.5% above the industry average. Given its robust revenue growth of 12.10%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of APYX increased by 140.28% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -3.31 to -9.66.
The secondary factor is the Revenue Growth, contributed 12.10%to the performance.
Overall, the performance of APYX in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
Frequently Asked Questions
Is Apyx Medical Corp (APYX) currently overvalued or undervalued?
Apyx Medical Corp (APYX) is now in the Fair zone, suggesting that its current forward PS ratio of 2.68 is considered Fairly compared with the five-year average of -10.15. The fair price of Apyx Medical Corp (APYX) is between 2.64 to 8.31 according to relative valuation methord.
What is Apyx Medical Corp (APYX) fair value?
APYX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Apyx Medical Corp (APYX) is between 2.64 to 8.31 according to relative valuation methord.
How does APYX's valuation metrics compare to the industry average?
The average P/S ratio for APYX's competitors is 6.61, providing a benchmark for relative valuation. Apyx Medical Corp Corp (APYX) exhibits a P/S ratio of 2.68, which is -59.50% above the industry average. Given its robust revenue growth of 12.10%, this premium appears unsustainable.
What is the current P/B ratio for Apyx Medical Corp (APYX) as of Jan 09 2026?
As of Jan 09 2026, Apyx Medical Corp (APYX) has a P/B ratio of 22.63. This indicates that the market values APYX at 22.63 times its book value.
What is the current FCF Yield for Apyx Medical Corp (APYX) as of Jan 09 2026?
As of Jan 09 2026, Apyx Medical Corp (APYX) has a FCF Yield of -6.61%. This means that for every dollar of Apyx Medical Corp’s market capitalization, the company generates -6.61 cents in free cash flow.
What is the current Forward P/E ratio for Apyx Medical Corp (APYX) as of Jan 09 2026?
As of Jan 09 2026, Apyx Medical Corp (APYX) has a Forward P/E ratio of -9.31. This means the market is willing to pay $-9.31 for every dollar of Apyx Medical Corp’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Apyx Medical Corp (APYX) as of Jan 09 2026?
As of Jan 09 2026, Apyx Medical Corp (APYX) has a Forward P/S ratio of 2.68. This means the market is valuing APYX at $2.68 for every dollar of expected revenue over the next 12 months.